Although less common in clinical practice, the detection of mutations in NOTCH1, ATM, and BIRC3 genes appears very valuable in assessing CLL patient prognosis in the era of chemoimmunotherapy, as BIRC3 mutations confer a 10-year survival rate of 29% [13], while NOTCH1 and ATM mutations have been associated with adverse prognostic effects [14]. Here, NOTCH1 is linked to B-cell chronic lymphocytic leukemia.